 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- KVA12123 / Kineta
A phase 1/2 clinical trial of antiVISTA (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_521;
P1/2
20230297 8. Advarra Study level: Pro00067861 All participants gave informed consent before taking part in this trial.
- Keytruda (pembrolizumab) / Merck (MSD), KVA12123 / Kineta
Interim results of the ongoing phase 1-2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (Section 48) - Mar 5, 2024 - Abstract #AACR2024AACR_3868;
Advarra Study level: Pro00067861 All participants gave informed consent before taking part in this trial. Abstract is embargoed at this time.
- | KVA12123 / Kineta
Journal, Checkpoint inhibition: A highly potent anti-VISTA antibody KVA12123 - (Pubmed Central) - Jan 1, 2024
These results establish that KVA12123 is a promising drug candidate with a distinct but complementary mechanism of action of the first generation of immune checkpoint inhibitors. This antibody is currently evaluated alone and in combination with pembrolizumab in a Phase 1/2 open-label clinical trial in patients with advanced solid tumors.
- Keytruda (pembrolizumab) / Merck (MSD), KVA12123 / Kineta
VISTA-101 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1110;
P1/2
Secondary objectives include characterizing PK, immunogenicity, and preliminary anti-tumor activity. Biomarker evaluation includes receptor occupancy, changes in immune cell markers and VISTA expression on collected biopsies.
- KVA12123 / Kineta
VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial (Section 39; Poster Board #23) - Mar 14, 2023 - Abstract #AACR2023AACR_2195;
This trial also includes a combination arm with pembrolizumab...More data are needed to confirm that high levels of soluble VISTA are associated with advanced disease.In the ongoing Phase 1/2 clinical trial, tumor tissues and serum samples will be collected from cancer patients prior to treatment with KVA12123 to inform the possible significance of these biomarkers. This work could help to better understand the response to KVA12123 in relation to the expression level of VISTA in cancer tissues as well as in the blood.
- |||| KVA12123 / Kineta
Enrollment open, Metastases: KEYNOTE-E67: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) (clinicaltrials.gov) - Mar 7, 2023
P1/2, N=314, Recruiting, Sponsor: Kineta Inc.
This work could help to better understand the response to KVA12123 in relation to the expression level of VISTA in cancer tissues as well as in the blood. Not yet recruiting --> Recruiting
- ||||| KVA12123 / Kineta
New P1/2 trial, Metastases: KEYNOTE-E67: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) (clinicaltrials.gov) - Feb 1, 2023
P1/2, N=314, Not yet recruiting, Sponsor: Kineta Inc.
- KVA12123 / Kineta
KVA12.1: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity. (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_761;
Conclusions The clinical trial will start by the end of 2022 and will evaluate the safety and tolerability of KVA12.1 injected alone or in combination with pembrolizumab, as well as the Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) as a primary objective. Pharmacokinetics, immunogenicity and tumor responses will also be evaluated in this trial.
- KVA 12.1 / Kineta
KVA 12.1 a novel fully human anti-VISTA antibody: Clinical trial design in monotherapy and in combination with an anti-PD1 antibody (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_889;
We are currently engaged in pre-IND studies and manufacturing of KVA12.1. Conclusions Here we are presenting the design of a phase 1/2 multicenter, open label, dose escalation and dose expansion study of intravenous infusion of KVA12.1 as a monotherapy and in combination with a fixed dose of an anti-PD1 antibody in patients with advanced refractory or metastatic solid tumors.